# Efficacy and Tolerability of Treatment With Alfalitic Plus Serenoa Repens Compared to Alfalitic Plus Antimuscarinic for Moderate-severe Lower Urinary Tract Symptoms

> **NCT07665749** · — · NOT_YET_RECRUITING · sponsor: **Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico** · enrollment: 50 (estimated)

## Conditions studied

- Benign Prostate Hypertrophy(BPH)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07665749
- **Lead sponsor:** Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-11-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07665749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07665749, "Efficacy and Tolerability of Treatment With Alfalitic Plus Serenoa Repens Compared to Alfalitic Plus Antimuscarinic for Moderate-severe Lower Urinary Tract Symptoms". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07665749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*